Nyxoah SA reported second quarter and first half 2026 financial results, securing $110 million in aggregate financing during Q2. Global net revenue reached €7.7 million in Q2, a 21% sequential increase, bringing H1 2026 total to €14.0 million compared to €2.4 million in the prior year period. U.S. commercial momentum drove a 22% sequential growth in U.S. net revenue to €5.2 million. The company activated 89 new high-volume accounts and trained 55 additional surgeons, resulting in 180 active accounts and 427 patients under prior authorization entering Q3. Cash and cash equivalents plus financial assets totaled €97.8 million at June 30, 2026. Nyxoah operates in the medical technology industry, developing and commercializing innovative solutions to treat Obstructive Sleep Apnea.

On June 17, 2026, Nyxoah SA received approximately $15.0 million (€13.8 million) from the second tranche of its existing loan facility with the European Investment Bank. Additionally, the company announced an extraordinary shareholders' meeting scheduled for July 9, 2026. Nyxoah SA is a medical device company that develops neuromodulation therapies.

Nyxoah SA entered into an underwriting agreement on June 5, 2026, for an underwritten public offering of 55,232,558 ordinary shares at $1.72 per share. The company expects to receive net proceeds of approximately $88.5 million after expenses.